This Journal Club will be discussing a study which aimed to estimate HCC incidence in F3/F4 patients in whom non-characterized liver nodules (NCLN) had been ruled-out before starting direct-acting antivirals and who achieved sustained virological response (SVR) with direct-acting antiviral.

Please log-in to your EASL Campus account to share your questions and comments using the chat below. The sound is muted per default, please hover your mouse over the video to enable the sound.

Want to share your opinion on Twitter? Please follow @EASLedu@aelsharkawy75 and use the #EASLJC for the latest updates.

ℹ️ By default the sound is muted, please pass the mouse over the player and activate the sound in the video control bar.

A chat is available to post your questions and interact with your peers. Please note that the following content is considered inappropriate and will be deleted by the EASL Campus Team:

  • foul language
  • person attacks
  • spam links
  • sensitive information (personal info, phone numbers, etc.)
  • links to executable files

Thank you for your understanding.


  • Elinam Gayi

    Inclusion >24 months after SVR was an exclusion criterion

  • Yu Jun Wong

    Do you assess fibrosis regression during the prospective follow-up and its impact on HCC occurance? Thank you.

  • Elinam Gayi

    Hello and welcome to the EASL Journal Club!
    If you have any questions just log in to your EASL Campus account and use this space.

Prof. HG
Henning Grønbæk
Educational Committee Member
Portrait of Dr. Elsharkawy
Ahmed Elsharkawy
Chair & Internal Affairs Councillor
Prof. Reig
Maria Reig
Senior Author
Dr Sanduzzi Zamperelli
Marco Sanduzzi-Zamparelli
Presenting Author
Dr Fabio Piscaglia
Fabio Piscaglia
The Challenger
Mattias Mandorfer
Moderator & YI Task Force Member
Potrait EG
Elinam Gayi
Medical Copywriter & Editor
Laurent Perrin
Laurent Perrin
Science & Education Coordinator
Mounia Heddad Masson
Head of Education & Science

Please login to access the resources.